Ebbutt A F, Elsdon-Dew R W
J Int Med Res. 1979;7(6):524-7. doi: 10.1177/030006057900700608.
A multicentre, open study of general practice patients with essential hypertension who were currently being treated with oxprenolol and cyclopenthiazide was undertaken in which the patients were transferred to Trasidrex for 12 weeks. Weight, blood pressure, heart rate and side-effects were assessed pre-trial and at 4-week intervals. A global assessment was also made at the same time intervals. The mean serum potassium remained virtually unchanged after 12 weeks treatment with Trasidrex. Blood pressure control was marginally improved during the study and it is thought possible that better patient compliance might explain this. Trasidrex was tolerated equally as well as the free combination.
对正在使用氧烯洛尔和环戊噻嗪治疗的原发性高血压全科患者进行了一项多中心开放性研究，研究中患者改用曲匹地尔治疗12周。在试验前及每隔4周对体重、血压、心率和副作用进行评估。同时也在相同时间间隔进行整体评估。使用曲匹地尔治疗12周后，平均血清钾基本保持不变。在研究期间血压控制略有改善，认为可能是患者更好的依从性对此做出了解释。曲匹地尔的耐受性与自由联合用药相当。
